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hypoglycaemia was no higher for those ≥65 y, with one case of
severe hypoglycaemia in a subject <65 y also treated with an SU.
CONCLUSION: In summary, in this ongoing open-label exten-
sion study, 2 y of exenatide treatment demonstrated similar
durable improvements in glycaemic control and weight reduc-
tion and safety proﬁles for those subjects ≥65 y compared to
younger subjects with T2DM treated with MET and/or SU.
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OBJECTIVES: The purpose of this study was to evaluate the
relationship between various diabetes treatment regimens and 1)
attainment of hemoglobin A1C (HbA1c) treatment goal, and 2)
treatment costs. METHODS: Pharmacy, medical, and laboratory
claims data from a large health plan in the Southeastern US from
1/1/2003–7/31/2006 were used. The index date was deﬁned as
the date of the last available HbA1c value, an indicator of
glycemic control during the previous 90 days. The study period
was deﬁned as the 120-day period that preceded the index date.
Goal was deﬁned as an HbA1c < 7.0. Treatment regimens were
categorized based on the number of diabetes-related medica-
tions: 1 oral, 2 orals, ≥3 orals, insulin, insulin plus 1 oral, insulin
plus 2 orals, and insulin plus ≥3 orals. Logistic and OLS regres-
sion models were used to identify predictors of goal attainment
and total treatment costs, respectively, after adjusting for poten-
tial confounding variables. RESULTS: A total of 18,905 patients
were included in the study, of which 50.9% were at goal. The
highest proportion of patients at goal was in the 1 oral group
(63.1%), while insulin plus 1 oral had the lowest (22.0%). After
adjusting for potential confounders, patients treated with regi-
mens that included insulin had a higher HbA1c value than those
only treated with oral medications. Those treated with insulin
were less likely to be at goal compared to those treated with one
oral (OR = 0.18, p < 0.0001). Similar results were found in other
insulin treatment groups. Predictors of increased total cost
included male sex, higher co-morbidity scores, and treatment
with multiple oral medications compared to one oral medication.
Increased compliance was associated with goal attainment (p <
0.0001) and lower total cost (p < 0.004). CONCLUSION: Only
50% of patients attained HbA1c goal. Increased compliance was
associated with goal attainment and lower costs.
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OBJECTIVES: Diabetes Mellitus II is one of the fastest growing
diseases in western countries. In Hungary about 5% of the pop-
ulation is diagnosed with DM II. Younger generations are at risk
of this disease when they eat unhealthy and physical activity
gains less attention in their life style. The objective of the study
is to measure the effect of dance as an aerobe movement on the
blood sugar level and compliance to medical therapy of adult
patients with DM type II. METHODS: The experimental study
design was used. 30 patients were selected randomly from the
Diabetes Club of Baranya County Hospital. Detailed medical
examination was carried out before and after the program. The
movement therapy program consisted of by the patients most
loved transformed dance styles based on the principles of phys-
iotherapy and coaching theories used by Beamer (2003). Muscle
strengthening and muscle mass improving techniques were used,
too. The actual blood sugar level and HbA1c level were moni-
tored during the 16 weeks program before and after the physi-
cal activity. For the statistical analysis Chi-square tests were used
with SPSS 11.0. RESULTS: The average age was 61.5 years
(Rmax:53;Rmin:75). In spite of the small sample size there is a
signiﬁcant change in the average blood sugar level between the
ﬁrst and the 16th weeks (p < 0.001). Due to the four-month
therapy, HbA1c level and actual blood sugar level remained in
the normal range. More than three days of break in the program
decreases the coaching effect signiﬁcantly. CONCLUSION:
Changing the health behavior and compliance among the elder
patients with DM II is difﬁcult. A “dance” coaching program
carried out with an appropriate intensity and frequency can com-
plete the medical therapy and rehabilitation of diabetes mellitus
type II effectively. The program can increase the well-being and
compliance of DM II patients.
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OBJECTIVES: Long-term studies of rosiglitazone (ADOPT) and
pioglitazone (PROactive) have reported average weight gain of
4.8 kgs and 3.6 kgs, respectively. This study assessed weighted
average gain in the body weight of type 2 diabetic patients due
to the use of thiazolidinediones (TZDs) over a short duration.
METHODS: Meta-analysis of published rosiglitazone and
pioglitazone clinical trials with duration up to 52 weeks. Initially,
trials with placebo as well as active comparator arms were iden-
tiﬁed through a systematic search of PubMed, EBSCO and 
Sci-lit databases. Each trial arm was treated as an independent
observation. Wherever possible, placebo-subtracted weight
change was computed for each arm of TZD trials. Exploratory
regression analysis was conducted using backward elimination
method to identify predictors of weighted average gain in the
body weight. RESULTS: Overall, 43 TZD trials yielded 60 trial
arms which represented 8,322 patients. Out of these, only 13
trial arms provided information sufﬁcient to compute the
placebo-subtracted weight gain. Weighted placebo-subtracted
gain in the body weight due to TZDs was 3.22 ± 7.16 kg. Sig-
niﬁcant predictors (b ± SE) of placebo-subtracted weight gain
(adjusted R2 = 0.73) were the use of TZDs as monotherapy (1.04
± 0.36), duration of diabetes in the treatment group in years
(0.25 ± 0.06) and rosiglitazone dose of 8 mg (1.36 ± 0.26). CON-
CLUSION: Patients using TZDs recorded mean weight gain of
3.22 ± 7.16 kg during short-term placebo-controlled clinical
trials. Duration of diabetes, use of TZD as monotherapy and
rosiglitazone dose of 8 mg were the only signiﬁcant predictors of
placebo-subtracted gain in the body weight. This weight gain is
highly undesirable in diabetics, due to high risk of experiencing
a cardiovascular event and potential adherence problems.
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